Trending...
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- 'Unity Through Christ Music Festival' coming to Detroit Saturday August 9, 2025
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Tetra Therapeutics, a Shionogi Group Company, focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, today announced the initiation of three Phase 2b/3 clinical studies of the investigational drug BPN14770 (zatolmilast) as a potential treatment for Fragile X Syndrome (FXS), the most common genetic form of autism. A selective small molecule inhibitor of phosphodiesterase‐4D (PDE4D), BPN14770 has shown positive results in a previous Phase 2 study in FXS in adult males (Berry-Kravis EM, et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med. 2021;27(5):862-870.). BPN14770 has also received Orphan Drug Designation from the U.S. Food and Drug Agency (FDA) for the potential treatment of FXS.
The Phase 2b/3 studies comprise two separate 150 subject, randomized, double-blind, placebo-controlled studies: one in an adolescent male population (ages 12-17), one in an adult male population (18-45), and a third open label extension study open to patients in both populations at the conclusion of the primary study. Endpoints for the studies include cognitive and behavioral assessments of the efficacy of BPN14770 by a variety of standard tests and determinations of the experimental drug's safety and tolerability. The study will also gather pharmacokinetic data on BPN14770. The studies are being conducted at multiple sites across the United States lead by principal investigator Elizabeth M. Berry-Kravis, M.D., Ph.D. at Rush University Medical Center, Chicago, Illinois. The studies are expected to be conducted over the next two years. Additional information is available through clinicaltrials.gov (Identifiers: NCT05163808, NCT05358886, NCT05367960).
More on Michimich.com
"We are excited to initiate these pivotal trials with BPN14770 in patients with Fragile X Syndrome, and are hopeful that the results of these studies will enable us to seek approval from FDA," said Chad Coberly, JD, Chief Executive Officer of Tetra Therapeutics.
"We are anxious to get started with these studies that offer hope for people living with Fragile X Syndrome and their caregivers," said Dr. Elizabeth Berry-Kravis, pediatric neurologist, Rush University Medical Center, and principal investigator. "Given our previous positive results with BPN14770 in the phase 2 study, we are hopeful these studies at a larger scale will show similar results. I find it exciting that we have a drug that potentially corrects a core deficit in FXS, a decrease in cAMP, that has been documented in patients as well as in the fly and mouse models of the disorder."
About BPN14770
BPN14770 is an investigational new drug that selectively inhibits phosphodiesterase-4D to enhance early and late stages of memory formation. Preclinical animal models show that BPN14770 has the potential to promote the maturation of connections between neurons, which is impaired in patients with FXS, and to protect connections between neurons which otherwise are lost in patients with Alzheimer's Disease. Tetra has completed investigational Phase 2 studies of BPN14770 in adults with FXS and in Alzheimer's disease. BPN14770 also has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).
About Tetra Therapeutics
Tetra Therapeutics, a Shionogi Group Company, is a clinical stage biotechnology company focused on developing a portfolio of therapeutic products to people suffering from Fragile X Syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. Tetra Therapeutics is headquartered in Grand Rapids, Michigan. For more information, please visit the company's website at http://www.tetratherapeutics.com.
More on Michimich.com
About Shionogi
Shionogi & Co., Ltd. is a 143-year-old global, research driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and wellbeing of the patients we serve." The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. S hionogi's research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en/.
Forward looking Statements
Certain other statements made throughout this press release that are not historical facts contain forward‐looking statements regarding the company's future plans, objectives and expected performance. Any such forward‐looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward‐looking statements.
Contacts
Tetra Therapeutics:
Chad Coberly, Chief Executive Officer
Tetra Therapeutics
info@tetratherapeutics.com
The Phase 2b/3 studies comprise two separate 150 subject, randomized, double-blind, placebo-controlled studies: one in an adolescent male population (ages 12-17), one in an adult male population (18-45), and a third open label extension study open to patients in both populations at the conclusion of the primary study. Endpoints for the studies include cognitive and behavioral assessments of the efficacy of BPN14770 by a variety of standard tests and determinations of the experimental drug's safety and tolerability. The study will also gather pharmacokinetic data on BPN14770. The studies are being conducted at multiple sites across the United States lead by principal investigator Elizabeth M. Berry-Kravis, M.D., Ph.D. at Rush University Medical Center, Chicago, Illinois. The studies are expected to be conducted over the next two years. Additional information is available through clinicaltrials.gov (Identifiers: NCT05163808, NCT05358886, NCT05367960).
More on Michimich.com
- Spanglish Entertainment Announces Inaugural Spanglish Party Cruise: A Celebration of Music and Culture
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
"We are excited to initiate these pivotal trials with BPN14770 in patients with Fragile X Syndrome, and are hopeful that the results of these studies will enable us to seek approval from FDA," said Chad Coberly, JD, Chief Executive Officer of Tetra Therapeutics.
"We are anxious to get started with these studies that offer hope for people living with Fragile X Syndrome and their caregivers," said Dr. Elizabeth Berry-Kravis, pediatric neurologist, Rush University Medical Center, and principal investigator. "Given our previous positive results with BPN14770 in the phase 2 study, we are hopeful these studies at a larger scale will show similar results. I find it exciting that we have a drug that potentially corrects a core deficit in FXS, a decrease in cAMP, that has been documented in patients as well as in the fly and mouse models of the disorder."
About BPN14770
BPN14770 is an investigational new drug that selectively inhibits phosphodiesterase-4D to enhance early and late stages of memory formation. Preclinical animal models show that BPN14770 has the potential to promote the maturation of connections between neurons, which is impaired in patients with FXS, and to protect connections between neurons which otherwise are lost in patients with Alzheimer's Disease. Tetra has completed investigational Phase 2 studies of BPN14770 in adults with FXS and in Alzheimer's disease. BPN14770 also has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).
About Tetra Therapeutics
Tetra Therapeutics, a Shionogi Group Company, is a clinical stage biotechnology company focused on developing a portfolio of therapeutic products to people suffering from Fragile X Syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. Tetra Therapeutics is headquartered in Grand Rapids, Michigan. For more information, please visit the company's website at http://www.tetratherapeutics.com.
More on Michimich.com
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Colbert Packaging Announces WBENC Recognition
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
About Shionogi
Shionogi & Co., Ltd. is a 143-year-old global, research driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and wellbeing of the patients we serve." The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. S hionogi's research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en/.
Forward looking Statements
Certain other statements made throughout this press release that are not historical facts contain forward‐looking statements regarding the company's future plans, objectives and expected performance. Any such forward‐looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward‐looking statements.
Contacts
Tetra Therapeutics:
Chad Coberly, Chief Executive Officer
Tetra Therapeutics
info@tetratherapeutics.com
Filed Under: Business
0 Comments
Latest on Michimich.com
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Critically Acclaimed Crime Drama Trap City, Starring Jeezy and Brandon T. Jackson Hits #1 on STARZ
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- CMR Mechanical Shares 5 Signs Your AC May Be in Desperate Need for Repair
- Michigan SEO Group Shares 5 Proven Ways to Boost Social Media Engagement for Small Businesses
- Mussio Painting Shares The Benefits of Working with Professional Painters in Ann Arbor
- Family Caregivers in Michigan Can Now Get Paid Through Medicaid with Family Aide Home Care
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns